🚀 go-pugleaf

Dernières parutions d'articles concernant le cancer de la prostate:
Most recent articles on prostate cancer:



Tradeoffs of integrating real-time tracking into IGRT for prostate
cancer treatment.
Zhu X, Bourland JD, Yuan Y, Zhuang T, O'Daniel J, Thongphiew D, Wu QJ,
Das SK, Yoo S, Yin FF.
Phys Med Biol. 2009 Aug 6;54(17):N393-N401.

New molecular biomarkers for the prognosis and management of prostate
cancer--the post PSA era.
Bickers B, Aukim-Hastie C.
Anticancer Res. 2009 Aug;29(8):3289-98.

Possible mechanism of CCL2-induced Akt activation in prostate cancer
cells.
Mizutani K, Roca H, Varsos Z, Pienta KJ.
Anticancer Res. 2009 Aug;29(8):3109-13.

Dietary supplement use and prostate cancer risk in the Carotene and
Retinol Efficacy Trial.
Neuhouser ML, Barnett MJ, Kristal AR, Ambrosone CB, King IB,
Thornquist M, Goodman GG.
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2202-6.
mneuhous@fhcrc.org

Alternative splicing and biological heterogeneity in prostate cancer.
Rajan P, Elliott DJ, Robson CN, Leung HY.
Nat Rev Urol. 2009 Aug;6(8):454-60.
p.rajan@beatson.gla.ac.uk

ETS gene fusions in prostate cancer.
Clark JP, Cooper CS.
Nat Rev Urol. 2009 Aug;6(8):429-39.
jeremy.clark@icr.ac.uk

Erectile dysfunction following prostatectomy: prevention and
treatment.
Magheli A, Burnett AL; Medscape.
Nat Rev Urol. 2009 Aug;6(8):415-27.

pT3N0M0 prostate cancer: a plea for adjuvant radiation.
Bolla M, Collette L.
Nat Rev Urol. 2009 Aug;6(8):410-2.
mbolla@chu-grenoble.fr

Genetic polymorphisms of estrogen receptors alpha and beta and the
risk of developing prostate cancer.
Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K.
PLoS One. 2009 Aug 5;4(8):e6523.
youngkwang.chae@gmail.com



























InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scimedweb@mail.com)